NASDAQ$BNGO

BioNano Genomics Inc · Q3 2020 earnings

Q3 2020 earnings · · Investor relations

Briefing

Bionano Genomics reported financial results for the third quarter of 2020.

Bionano Genomics reported a total revenue of $2.2 million for Q3 2020, which is up 86% sequentially from the prior quarter, but down 33.7% compared to the same period in 2019. The company's cash and cash equivalents were $18.9 million as of September 30, 2020, compared to $17.3 million at the end of 2019. The company also acquired Lineagen, which added $0.4 million to revenue.

  • Total revenue was $2.2 million, up 86% sequentially from the prior quarter.
  • Lineagen acquisition added $0.4 million to Q3 revenue.
  • Cost of revenue decreased by 38.5% to $1.5 million compared to the same period in 2019.
  • Cash and cash equivalents were $18.9 million as of September 30, 2020.

Headline financials

Total Revenue

$2.2M

Previous: $3.31M-33.7%
EPS (adj)

-$0.80

Previous: -$5.90+86.4%
Capital Expenditures

$0.00

Previous: -$38.4K+100.0%
Free Cash Flow

-$10.8M

Previous: -$6.44M-67.7%
Net Income

-$10.8M

Previous: -$6.4M-68.7%
Operating Income

-$10.2M

Previous: -$5.69M-79.9%
Gross Profit

$736K

Previous: $938K-21.5%
Cash & Equivalents

$18.9M

Previous: $8.22M+129.4%
Total Assets

$41.4M

Previous: $19.2M+115.5%
Stock-Based Comp

$447K

No prior period

Revenue & EPS history

BioNano · Revenue · Quarterly

$2.2M

Q3 2020-33.7%vs Q3 2019
Beat estimate in 12 of 12 quarters(100%)
ActualEstimate

Revenue by segment

BioNano · $2.2M total across 2 segments · Q3 2020

  • Product Revenue
    $1.58M-50.0%
  • Service and Other Revenue
    $616K+307.9%

Forward guidance

No forward guidance was provided in the earnings report.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 18 quarterly earnings reports · overlaid with Q3 2020

Historical avgQ3 2020

-3.3%

Avg return

Earnings day

-5.4%

Avg return

5 days after

-7.7%

Avg return

30 days after

40%

12 / 30 earnings

Positive

+15.5%

Q4 2018

Best reaction

-29.8%

Q4 2019

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2025+0.9%+1.6%
Q1 2026-0.8%-9.5%-7.9%
Q3 2025+2.8%+4.8%+10.2%
Q1 2025+2.9%+0.8%-2.4%
Q4 2024+11.1%+8.6%+43.4%
Q3 2024-3.4%-11.5%-7.7%
Q2 2024-21.5%-23.5%-13.7%
Q1 2024+2.7%+7.3%-9.4%
Q4 2023+0.0%-5.8%-18.2%
Q3 2023-7.0%-10.5%+2.8%
Q2 2023-0.2%-13.9%-15.7%
Q1 2023+6.9%-9.6%+0.0%
Q4 2022-8.4%-5.3%-19.8%
Q3 2022+2.7%+2.2%-6.3%
Q2 2022+6.6%+0.0%+2.2%
Q1 2022-16.1%-24.2%-10.8%
Q4 2021+1.4%-10.7%+20.6%
Q3 2021-9.8%-13.7%-44.4%
Q2 2021+5.4%+4.4%-1.0%
Q1 2021+13.9%+22.8%+59.9%
Q4 2020-17.9%-14.4%-34.1%
Q3 2020-7.4%-5.4%-10.7%
Q2 2020-8.4%-6.5%-32.5%
Q1 2020-8.4%-11.8%+21.6%
Q4 2019-29.8%-30.3%-74.3%
Q3 2019-2.1%+17.8%+24.4%
Q2 2019-14.4%-11.3%-50.5%
Q1 2019-11.3%-17.0%-28.1%
Q4 2018+15.5%+7.4%-8.1%
Q3 2018-6.0%-5.7%-11.9%
Q2 2018
Q1 2018
Q4 2017
Q3 2017
Q2 2017
Q1 2017

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro